FAKTOR-OPTIONSSCHEIN - GILEAD SCIENCES | Real-time Bid/Ask 07:50:43 2024-06-24 EDT | ||
| 11.3 EUR / 11.44 EUR | -0.70% |
|
| Current month | +24.32% | ||
| 1 month | +12.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-24 | 11.3 | -1.31% |
| 24-06-21 | 11.45 | +6.91% |
| 24-06-20 | 10.71 | +19.13% |
| 24-06-19 | 8.99 | -1.10% |
| 24-06-18 | 9.09 | -4.82% |
Delayed Quote Börse Stuttgart
Last update June 24, 2024 at 07:07 am
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | Morgan Stanley |
| WKN | MD4BGX |
| ISIN | DE000MD4BGX9 |
| Date issued | 2022-05-10 |
| Strike | 35.36 $ |
| Maturity | Unlimited |
| Parity | 2.9 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.66 € |
|---|---|
| Lowest since issue | 8.68 € |
| Spread | 0.06 € |
| Spread % | 0.53% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
70.67
USD
Average target price
82.89
USD
Spread / Average Target
+17.29%
- Stock Market
- Certificates
- Certificat
